Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
169.08
+0.94 (+0.56%)
Streaming Delayed Price
Updated: 10:59 AM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
10 Health Care Stocks Whale Activity In Today's Session
July 10, 2024
Via
Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
The 7 Best Warren Buffett Stocks to Buy in July 2024
July 09, 2024
Some investors may say value investing is dead, but its never a bad time to look at some of the best Warren Buffett stocks to buy
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
July 08, 2024
Via
Benzinga
A Closer Look at AbbVie's Options Market Dynamics
July 03, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
July 02, 2024
Via
Benzinga
The Smartest Dividend Stocks to Buy With $250 Right Now
July 08, 2024
$250 will go a long way with these great dividend stocks.
Via
The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Via
Benzinga
Topics
ETFs
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
AbbVie Stock: A Perfect Dip for Investors to Buy
July 03, 2024
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Via
MarketBeat
Topics
ETFs
Looking At AbbVie's Recent Unusual Options Activity
June 27, 2024
Via
Benzinga
Check Out What Whales Are Doing With ABBV
June 21, 2024
Via
Benzinga
New Golden Investment: Universal Health Realty Income Trust
July 03, 2024
A Golden Investment is one in which I have fully recovered my entire investment either through dividends or from partial liquidation or a combination of both.
Via
Talk Markets
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
July 02, 2024
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
July 02, 2024
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three.
Via
InvestorPlace
3 Retirement All-Stars for Steady Growth and Income
July 01, 2024
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Cash Flow Alert: 3 Stocks That Just Raised Their Dividends
July 01, 2024
These dividend growth stocks all have a long history of double-digit dividend increases and just announced another.
Via
InvestorPlace
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
July 01, 2024
These reliable dividend payers are no-brainer buys right now.
Via
The Motley Fool
3 Magnificent Stocks Retirees Can Buy and Hold Forever
July 01, 2024
These stocks could be ideal for investors in their golden years.
Via
The Motley Fool
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
June 30, 2024
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice.
Via
InvestorPlace
7 Dividend Kings to Buy With Your Roth IRA Money in 2024
June 28, 2024
These seven Dividend Kings offer reliable income streams and long-term growth potential, making them ideal holdings for your Roth IRA.
Via
InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
Via
Benzinga
Exposures
Product Safety
Can AbbVie Stock Keep Outpacing the S&P 500?
June 27, 2024
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
June 25, 2024
Via
Benzinga
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock
June 25, 2024
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues. ABBV-951, a treatment for advanced Parkinson's, is approved in 34...
Via
Benzinga
Exposures
Product Safety
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
June 25, 2024
Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.
Via
The Motley Fool
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
June 24, 2024
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets.
Via
InvestorPlace
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
June 22, 2024
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend.
Via
Talk Markets
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
June 22, 2024
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.